Mutations in the alpha 2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide by unknown
MUTATIONS IN THE a2 HELIX OF HLA-A2 AFFECT
PRESENTATION BUT DO NOT INHIBIT BINDING
OF INFLUENZA VIRUS MATRIX PEPTIDE
By KEVIN T. HOGAN,' NAOKI SHIMOJO,l SCOTT F. WALK,`
VICTOR H. ENGELHARD,* W. LEE MALOY,4 JOHN E. COLIGAN,§
AND WILLIAM E. BIDDISONI
From the 'Department of Microbiology, University of Virginia School of Medicine, Charlottesville,
Virginia 22908, the TNeuroimmunology Branch, National Institute of Neurological,
Communicative Disorders, and Stroke, National Institutes of Health; and the §Biological Resources
Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health,
Bethesda, Maryland 20892
Knowledge of the mechanism by which class I-restricted CTL recognize target
cells has been significantly advanced by two recent findings. First, Townsend et al.
(1, 2) demonstrated that target cells that had been incubated with short synthetic
peptides corresponding to sequences ofthe influenza nucleoprotein (NP)' molecule
couldbe specifically recognized by class I-restricted, NP-specific CTL. These initial
findings were subsequently extended to include CTL recognition of a number of
peptides derived from viral molecules (3, 4) and alloantigens (5-7). These observa-
tions suggested that class I molecules bind and present peptide fragments to CTL
by a mechanism that is as yet indistinguishable from that by which class II mole-
cules present peptide antigens to Th (8-10). Secondly, Bjorkman et al. (11, 12) have
resolved the protein structure ofthe humanclass I molecule HLA-A2 by x-ray crys-
tallography. In this structure, the al and a2 domains interact to form a platform
consisting ofa 0-pleated sheet floor over which lie two a helices with a long groove
between them. Thelocation, size, and shape ofthis groove is consistent withits pro-
posed function as a peptide binding site. In fact, an electron-dense region (possibly
a peptide) ofunknown origin was found in this putative peptide binding site in the
HLA-A2 crystal. Thus, it was suggested that class I molecules can bind peptides
and present them to T cells in an analogous way that class II molecules have been
shown to bind and present antigen (12).
To further analyze the role ofclass I molecules in the presentation ofpeptide an-
tigens, wehave examined the ability ofpeptide-specific CTL to recognize site-directed
mutants ofHLA-A2. A naturally occurring variant ofA2.1 (DKl-A2.3) was previ-
ously identified byits inability tobe recognized byA2.1-restricted influenza-specific
CTL (13, 14). Characterization of the A2.3 gene (15, 16) has shown that these two
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molecules differ at amino acid residues 149, 152, and 156. The side chains of amino
acids at positions 152 and 156 point into the putative peptide binding site, whereas
the side chain of the amino acid at position 149 points up and away from the site
(11, 12). In this study, we have examined whether these substitutions affect the ability
of the A2 molecule to present peptide to A2.1-restricted CTL. To do this, we have
taken advantage of the finding that the major component of the A2.1-restricted CTL
response to the type A influenza virusA/JAP/57 is the recognition of a single matrix
protein peptide, Ml 55-73 (3). Using human target cells transfected with site-directed
mutants of the A2 .1 gene, we have analyzed the effects of substitutions at positions
149, 152, and 156 on the ability of the A2 molecule to present this M1 peptide to
peptide-specific CTL.
Materials and Methods
Cells.
￿
PBL were obtained by batch leukapheresis of normal adult volunteers (13) . HLA
serotyping of PBL was kindly performed by the Human Leukocyte Antigen Typing Lab,
Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD. JY and
M16B are Epstein-Barr virus-transformed B cell lines.
Mutagenesis and Transfection.
￿
Site-directed mutagenesis was performed as described by Kunkel
(17) and will be described in more detail elsewhere (Hogan et al., manuscript in preparation).
Briefly, a 212-bp KpnI fragment encoding amino acids 113-182 of the HLA-A2.1 gene was
subcloned into the vector M13mp19. Oligonucleotides were synthesized such that they con-
tained a mismatched nucleotide at the site to be mutated and were annealed to the single-
stranded template DNA. A complete second strand was then synthesized by in vitro primer
extension. After in vivo selection of phage containing mutant DNA (17), the mutants were
confirmed and identified by Sanger dideoxy sequencing (18) . KpnI inserts containing mul-
tiple mutations were generated by additional cycles of mutagenesis with the appropriate oli-
gonucleotides. The KpnI fragment was then reinserted into a plasmid vector containing the
complete A2.1 gene, but with the corresponding 212-bp KpnI fragment deleted. Plasmids
containing the inserted fragment in the correct orientation were identified by restriction map-
ping. To ensure that the proper fragment had been subeloned, the same fragment was re-
moved from the putative mutant DNA, subcloned into M13mp18 or M13mp19 and resequenced.
The A2 mutants used in this study are described in Table I. The nomenclature used is the
single letter code for the amino acids at positions 149, 152, and 156. Underlined residues
indicate those amino acids that are different from those found in A2.1.
The cell line used for transfections was HMy2 .CIR (HMy), a class I - deletion mutant
ofthe human plasma cell leukemia line LICR.LON.HMy2 (19) (kindly provided by Dr. Peter
Cresswell, Duke University, Durham, NC). An Eco RI/Bam HI fragment containing the
neomycin resistance gene was subcloned from pKOneo into each of the mutant genes. DNA
(20-40 ug) was transfected into 5 x 106 HMy cells by electroporation (20). Cells were selected
in culture with 600 wg/ml geneticin G418 (Gibco Laboratories, Grand Island, NY). Trans-
fectants expressing high levels of mutant molecules were identified by RIA and FACS anal-
ysis. High expressors were then subcloned by limiting dilution to ensure the clonality of the
cell population. The cells were periodically screened to ensure stable expression of the mu-
tant gene products.
FACSAnalysis of Transfectants.
￿
Cell surface expression of transfected A2 genes was assessed
by indirect immunofluorescence using a FACS IV (Becton Dickinson & Co., Sunnyvale, CA).
Cells were incubated with a saturating amount of the A2-specific mAb BB7 .2 (21, a 1:1,000
dilution ofascites), washed, and then incubated with fluorescein-labeled anti-mouseIg (Cappel
Laboratories, West Chester, PA) as previously described (22). The results of these assays are
shown in Fig. 1. All transfectants expressed similar levels of cell surface A2 .
Synthetic Peptides. Synthetic peptides that correspond to the sequences 55-73
(LTKGILGFVFTLTVPSERG) and 57-68 of the Ml protein (3) and 181-204 (INETEQRT
LYENVGTYVSVGTSTL) of the hemagglutinin (HA) of A/JAP influenza virus (23) wereto.
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TABLE I
Class I Genes Usedfor Transfection
DNA and amino acid sequences of A2 .1, A2.3, and the site-directed mutants
of A2.1 . The nomenclature of the mutants is such that each ofthe three letters
corresponds to the single letter amino acid code for positions 149, 152, and 156.
Underlined residues indicate a substitution relative to A2.1 .
synthesized by automatic solid phase synthesis on a peptide synthesizer (model 430A; Ap-
plied Biosystems, Inc., Foster City, CA) or were purchased from Peninsula Labs (South San
Francisco, CA). M1 peptides were extracted with aqueous volatile buffer, lyophilized to dry-
ness, and used without further purification (24).
Generation andAssay ofCTL.
￿
PBL from A2.1-positive individuals (3 x 106) were cultured
in vitro with 5 ug/ml M1 57-68 peptide (N3.4 gM) for 9 d in 2 ml of culture medium [RPMI
1640 (Gibco Laboratories) supplemented with 2 MM L-glutaminc, 100 U/ml penicillin, 100
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FIGURE 1.
￿
FRCS analysis of HMy transfected cells. Untransfected HMy and transfected cells
were analyzed with A2-specific rnAb BB7.2 by indirect immunofluorescence . Solid lines are profiles
of cells stained with BB7.2 plus Fl-anti-1g, and dotted lines are profiles of cells stained with Fl-
anti-Ig alone. The amino acids at positions 149, 152, and 156 are used to identify each of the
transfected genes. Underlined residues designate amino acids that are different from those found
in the A2.1 gene.
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A2.1 = AVL Ala Val Leu
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A2 .3 = TT_EWW _T_hr Glu _Trp
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_TVL _T_hr Val Leu
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A_EL Ala _Glu Leu
(GAG)
AVW Ala Val Trp
(TGG)
TVW Thr Val Trp
(ACG) (TGG)
A_AL Ala _Ala Leu
(GCG)728
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wg/ml streptomycin, and 10% pooled heparinized human plasma] in 24-well tissue culture
plates (Nunc, Roskilde, Denmark). 5 U/ml rIL2 (Cellular Products, Buffalo, NY) were added
on day 3 of culture. On day 10, the primed responder cells were restimulated in secondary
culture : 106 responder cells and 9 x 106 irradiated autologous PBL (2,000 rad) were cultured
in the presence of 5 4g/ml Ml 57-68 peptide and 5 U/ml rIL-2 for 5 d in 10 ml of culture
medium in upright 25-cm' flasks (Nunc). Tertiary and quaternary stimulations of responder
cells were done exactly as described for the secondary stimulation. Aftersecondary stimula-
tion, responder cells were plated in limiting dilution culture (25) at 10 cells per well or 1
cell per well in the presence of 5 wg/ml Ml peptide 57-68, 25 U/ml rIL-2, and irradiated
A2 .1-positive PBL (2,000 rad).
The generation of the A2-specific alloreactive CTLline B12.A2.C5 has been described(26).
The HLA-DPw4-specific CTL line H9 anti-W7 (27) was kindly provided by Dr. Stephen
Shaw, NIH, Bethesda, MD.
CTL activity was measured in a standard 4-5-h "Cr-release assay (22). For preparation
of targets with the Ml peptide, cells were incubated for 18 h (unless otherwise stated) with
100 PCi of Na2`CrO4 (New England Nuclear, Boston, MA) and an optimal concentration
(5 wg/ml, -2.2 gM) of Ml 55-73 peptide(in preliminary experiments, this peptide was shown
to be slightly better for sensitizing targets than the 57-68 peptide) . Targets were then washed
twice, counted, and plated in the presence of 10 ug/ml M1 55-73 peptide for the duration
of the CTL assay. In some cases, targets were also infected with A/JAP/57 or B/Ann Arbor
influenza viruses (22) rather than being pulsed with Ml peptides. Results are expressed as
the mean percent specific lysis of triplicate determinations (22).
Results
Generation and Specificity of HLA-A2.1-restricted M1 Peptide-specific CTL.
￿
PBL from
A2.1-positive individuals were stimulated in primary in vitro culture with 5 wg/ml
M1 57-68 peptide in the presence or absence of 5 U/ml HL-2. CTL activity was
assessed on A2-matched JY target cells incubated with or without M1 55-73 pep-
tide. The results of one experiment with three different individuals are shown in
Fig. 2. CTL activity could be detected in PBL populations stimulated with peptide
plus rIL-2, but little or no activity was generated in the absence ofrIL-2. No cyto-
lytic activity was detected on target cells that had been incubated without peptide.
MI peptide-primed cells restimulated in secondary, tertiary, and quaternary cul-
tures gave a similar reactivity pattern (data not shown) .
CTL lines generated in limiting dilution culture were established from these bulk
restimulations. The antigen specificity ofa representative CTL line is shownin Fig.
3. This CTL line specifically lysed A2.1-matched targets (JY) incubated with the
Ml 55-73 peptide but did not lyse the same targets incubated with an unrelated
antigenic A/JAP peptide HA 181-204. The A2.1-negative target M16B that was in-
cubatedwith theMl peptidewas notlysed.JYtargets infectedwith A/JAP influenza
virus, from which the MI 55-73 sequencewas derived, were lysed, whereasJY targets
infected with B/Ann Arbor influenza virus were not lysed. These results demon-
strate that MI peptide, in the presence of rIL-2, can stimulate CTL that are able
to specifically recognizeA/JAP-infected A2-positive targets, as well astargets sensi-
tized with the M1 55-73 peptide.
Ml-Peptide-specific CTLRecognition ofA2 Transfectants.
￿
A2.1-restricted CTL specific
forthe M1 peptide 57-68were generatedinsecondary and quaternary bulkcultures
and in limiting dilution culture. These CTL populations were assayed on the series
of HMy transfectants described in the Materials and Methods section and shown
in Fig. 1. The transfectants expressed A2.1 or site-directed mutants ofthe A2.1 geneJ
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that encoded molecules that differed by amino acids at positions 149, 152, and/or
156 (see Table I). The results shown in Fig. 4 (A-C) are representative ofresults ob-
tained with 14 CTL lines generated in secondary or quaternary bulk cultures and
11 CTL lines generated in limiting dilution culture. All the CTL lines lysed A2.1
but not A2.3 (TEW) transfectants or untransfected cells that were incubated with
M1 55-73 peptide. MutantsAEL andAVW, whichexpressedthe A2.3 residues Glu
at position 152 and Trp at position 156, respectively, were not lysed. The double
mutant T_V_W, which expressed the A2.3 residues Thr at 149 and Trp at 156, also
was not lysed. These results demonstrate that the introduction ofsingle amino acid
substitutions atpositions 152 or 156 can dramatically alterthe ability oftheA2 mol-
ecule plus M1 55-73 peptide to be recognized by this group of CTL. In contrast,
the presence ofthe A2.3-derived residue Thr at position 149 did not have a similar
effect as the site-directedmutant TVL was lysed byall theCTLlines. Intheabsence
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FIGURE 2.
￿
Generation of influenza virus M1
peptide-specific CTL. A2.1' PBL from three
different individuals; Q53, (A); Q63, (B); and
Q82, (C)were stimulated in 7-dprimarycultures
with peptide M1 57-68with (")or without (A)
rJL2 . Effector populations were assayed on
A2.1+ target JY that was incubated with 10
gg/ml Ml 55-73 (", A) or no peptide (o).
FIGURE 3.
￿
SpecificityofMl peptide-specific CTL. CTL
line Q44.3B3 wasgeneratedagainstA2.1 plus Ml 57-68
peptide in limiting dilution culture at 10 cells/well and
assayed on A2.1+ JY targets that were either incubated
with Ml 55-73 peptide, A/JAP influenza HA 181-204
peptide, or were infected with A/JAP or B/Ann Arbor
virus. Targets also included A2 .1 - target M16B in-
cubated with Ml 55-73 peptide. E/T ratio, 28:1.
r-~
JY + JY + M160 + JY + JY +
MS HA MI A/JAP B/AA
55-73 181-204 55-73
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ofpeptide, nolysis ofTVL was observed (data not shown). One mutant, AAL, was
of particular interest because it contained an Ala for Val substitution at position
152. This substitution resulted inthe loss oftwo methyl groups at this position, and
is considered to be a relatively conservative substitution. The observation that the
AAL mutant transfectant plus Ml peptidewasnot recognized byMl 55-73 peptide-
specific A2.1-restricted CTL indicatesthat aconservativechange at position 152 can
have amajoreffect on recognition. In summary, amino acid changes thatwere made
at positions 152 and 156haddramatic effects onT cell recognition, whereasthe change
made at position 149 had little effect.
1 CTL line outofthe 25 that were tested fromninedifferent individuals wasfound
to have a significantlydifferent reactivity pattern withthe site-directedmutants than
was describedabove. Secondary CTL bulk cultures from donorQ66(Fig. 4D) lysed
A2.1 and _TVL transfectants butnot the A2.3 (TEW) or 152 mutant A_EL transfec-
tants or untransfected HMy cells plus M1 peptide, as was observed for the other
FIGURE 4.
￿
Recognition of HMy transfectants by A2 .1
plus Ml 55-73peptide-specific CTL. CTLlines gener-
ated in secondary culture against Ml 57-68 peptide
(Q53, A, Q66, D), quaternary culture (Q44, B), and
in limiting dilution culture at 10 cells/well (Q44.3B6,
C) were assayed on the indicatedpanel oftransfectants
that had been incubated with 5 wg/ml of M155-73. E/T
ratios were: (A, B, and D) 10:1; (C) 9:1. Underlined
residues are those that are different from A2 .1 .
FIGURE 5.
￿
Effect ofThr substitution
forAlaat position 149. A2 .1-restricted
Ml 55-73 peptide-specific CTLclones
Q44.IC5 (A)andQ44.3B6 (B)were as-
sayed on 2.1 (AVL, ")andT_VL (0)
transfectants (E/T ratio, 5:1) that were
either preincubated for 18 h with 5
gg/mlMl 55-73 or 2.1 (AVL, ") and
T_VL (o) transfectants that were not
preincubated with peptide butwere ex-
posed to various doses of MI 55-73
during the 4-h CTL assay.J
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FIGURE 6.
￿
Susceptibility oftransfectants to lysis by allo-
specific CTL. Transfectants were assayed as targets for
anti-A2 allospecific CTL line B12.A2.C5 (A, E/T ratio,
2.5 :1) and anti-DPw4-specific CTL line H9 anti-W7 (B,
E/T ratio, 10:1).
CTL lines. In contrast, these CTL were able to lyse transfectants that express the
single mutants AVWand AAL aswell as the double mutant TVW. Nolysis ofthese
mutants was observed in the absence ofMl peptide (data not shown). These results
indicate that A2 molecules with substitutions ofeither Thr for Ala at position 149,
Ala for Val at 152, or Trp for Leu at position 156 can still present the Ml peptide
to some Tcells. Therefore, the lack ofrecognition ofthese mutants by the majority
of peptide-specific A2.1-restricted CTL is not due to loss of peptide binding.
The observation that the mutant trunsfectant TVL was lysed by all CTL lines
that were tested (Fig. 4) suggested that this substitution had little or no effect on
recognition ofthe Ml 55-73 peptide. Inthese experiments, targets were preincubated
with peptide for 18 h before the CTL assay. However, significant differences were
observed between theA2.1 and TVL transfectantswhenthesetargetswere incubated
with Ml 55-73 peptide immediately before the CTL assay (Fig. 5). Both targets
could be lysed by Ml-specific CTL lines under normal assay conditions, but only
the A2.1 transfectant was lysed when increasing amounts ofthe Ml 55-73 peptide
were added immediately before the CTL assay. These results indicate that the sub-
stitution ofa Thr foran Alaresidue at position 149 may affect the kinetics ofbinding
ofthe Ml 55-73 peptide to the A2 molecule. This substitution may also affect the
binding affinity forpeptide(s) that are already bound to the A2 molecule and must
be displaced before the M1 55-73 peptide can associate.
Reactivity ofSite-directedMutantswith Control CTLPopulations.
￿
To determine whether
the inability of some of the transfected cells (e.g., TEW, A_EL) to be lysed by the
A2.1-restricted Ml peptide-specific CTL was due tosomegeneraldefect in theirability
to be recognized by T cells, two different control CTL populations were examined.
The first control population was an alloreactive A2-specific CTL line (B12.A2.C5)
that recognizes both A2.1 and A2.3 (Fig. 6 A). This CTL line lysed the _T_EW and
the A_EL transfectants as well or better than the A2.1 transfectant . The TVL trans-
fectant, which waslysed byall tested Ml peptide-specific CTL, wasnot significantly
more susceptible to lysis than the other transfectants. Analysis of all the transfec-
tants with a DPw4-specific CTL line (Fig. 6 B) indicated that all ofthese cells were732
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very similar in their susceptibility to lysis. Collectively, these results indicate that
there are no obvious differences in the susceptibility ofthe target cells in this panel
to CTL-mediated lysis.
Discussion
The results in this paper demonstrate that individual amino acid changes that
occurbetweenA2.1 and A2.3 have aneffect on the ability ofthese molecules to present
the Ml 55-73 peptide to peptide-specific A2.1-restricted CTL. In particular, single
amino acid substitutions that replace residues 152 or 156 ofthe A2.1 molecule with
those found in A2.3 inhibit the ability ofmost peptide-specific A2.1-restricted CTL
to recognize thesemolecules. In contrast, a single amino acid substitution at residue
149 had relatively minor effects on CTL recognition. Although no direct evidence
has been presented that class I molecules can bind antigenic peptides, it has been
assumed that such binding occurs and that the side chains of the amino acids that
pointinto the putative bindingsite are involved in antigenpresentation (11, 12). The
amino acids at positions 152 and 156 are on the a helix ofthe a2 domain and are
oriented such that their side chains point into the putative peptide binding site (11,
12). Both of these residues could be ligands for peptide binding or they could be
important for binding by the TCR. Therefore, changes in the side chains ofthese
amino acidscouldhave several possibleeffects: (a) abolish the ability ofthe molecule
to bind an antigenic peptide; (b) change the conformation of the peptide that is
presented to the TCR; or (c) alter the part ofthe A2 molecule that directly contacts
the TCR.
The effects of the substitutions ofVal - Ala at 152 (AAL), Leu - Trp at 156
(AVW), and both Ala -" Thr at 149 and Leu - Trp at 156 (TVW) could not be
attributed to a failure ofthese mutant molecules to bind the Ml 55-73 peptide, be-
cause one Ml-specific CTL population was found that could recognize target cells
that express these molecules after incubation with the peptide. Thus, the failure of
these moleculestobe recognized bytheotherMl-specific CTLlinesmay result from
achange in the conformation ofthe Ml 55-73 peptide that is presented to the TCR.
Alternatively, these mutations may alter the ability ofthe TCR to directly interact
with the A2 molecule.
The substitution at position 152 ofAla (with side chain ofCH3) forVal (with side
chain of -CH-[CH3]2) resulted in the loss of recognition by all but one of the Ml-
specific CTL lines that were analyzed. Because this is a relatively conservative sub-
stitution, it seems more likely that this change would result in an alteration ofthe
conformation of the bound peptide, or the position ofthe peptide in the binding
pocket rather than having major effects on the ability of the TCR to bind to the
complex of the M1 peptide with the A2 molecule. However, it is possible that the
side chain of amino acid 152 provides an important contact point with the TCR
in combination with an adjacent residue of the peptide. It was also observed that
the A_EL transfectant with the substitution of Val - Glu at position 152 was not
recognized by any ofthe Ml-specific CTL, including the Q66 CTL population. Al-
though this substitutioninvolvesacharge difference, wehave also obtainedthe same
results using transfectants with a Gln substitution at position 152 (data not shown).
Collectively, these results suggest that amino acid residue 152 is critically involved
in either binding of the M1 55-73 peptide or interacting with the TCR. TheHOGAN ET AL.
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significance ofthe amino acid at position 152 for T cell recognition ofclass I mole-
cules has also been shown by results ofstudies using site-directed mutants ofHLA-
A3 (26).
The substitution ofthe A2.3 residue Trp for the A2.1 residue Leu at position 156
had the same effect as the Ala for Val substitution at position 152: only one of the
MI-specific CTL lines could recognize this mutant. Unlike the substitution ofAla
for Val, which results in a slightly smaller but structurally similar side chain, the
change at position 156 involves the substitution ofthe large indole ring of Trp for
the branched aliphatic side chain of Leu. Despitethe fact that thisrepresentsamajor
change in the size and structure ofthe side chain at this position, this mutant could
still bind the M1 55-73 peptide. This may indicate that this residue does not play
an important role in the binding of the peptide, or that its role depends upon the
strong hydrophobic character of both Leu and Trp. Inclusion ofan additional sub-
stitution of Ala -Thr at position 149 in the double mutant _TV_W did not destroy
the ability of the molecule to be recognized by the Q66 CTL. Although obtained
with a limited number of CTL, this result in conjunction with the findings using
the mutant A_EL, suggest that, ofthe amino acid residues that differ between A2.1
and A2.3, position 152 exerts the strongest effect on T cell recognition.
The side chain ofthe amino acid at position 149 points up and away from the
proposed peptide binding site (11, 12). The substitution of Ala - Thr at position
149 has been shown to inhibit the binding ofone A2/A28-specific mAb CR11-351
(28), suggesting that this residue is on the outer surface of the A2 molecule. This
substitution did not abolish the ability ofthe molecule to be recognized by any of
the M1-specific CTLlines, although in most lines, thelevel oflysis on the_TVLtrans-
fectant was less than on the A2.1 transfectant. However, this substitution did have
an effect on the ability ofthe M1 55-73 peptide to associate with the A2 molecule,
since the _TVL mutant transfectant (unlike the A2.1 transfectant) could not be rec-
ognized when the peptide was added immediately before the CTL assay. This indi-
cates that this substitution may affect the kinetics with which the M1 55-73 peptide
associates with the A2 molecule. This result also suggests either that residues that
are apparently not directly in the peptide bindingpocket (based on thecrystal struc-
ture [11, 12]) may nonetheless contact part of the peptide or that they may produce
indirect effects on other residues that are involved in peptide binding.
The present analysis ofT cell recognition ofthe A2 molecule has used CTL that
have been generated against a synthetic peptide, M1 55-73, that corresponds to a
sequence ofthe influenza A/JAP/57 Ml protein. Nevertheless, these CTL appar-
ently recognize anaturally-occurring antigen, since they are able to specifically lyse
A/JAP/57-infected target cells. CTL that are specific for the M1 peptide have not
been generated from individuals who are A2- (data not shown), indicating that this
peptide can only be recognized by T cells that are restricted by A2.1 or other class
I molecules that are very rare in the population . We have been unable to generate
readily measurable CTL responses to the M1 peptide in the absence ofrIL-2, pre-
sumably because this peptide is not recognized in the context ofclass II molecules
and, therefore, does not induce a Th response. The observation that anti-M1 pep-
tide CTL are readily generated from most A2' individuals that have been tested
may reflect the fact that most adults have been multiply primed in vivo with cross-
reactive type A viruses. Thus, the in vitro responses that we are generating are most
likely derived from memory CTL.734
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Although no direct evidence has been presented that class I molecules can bind
antigenic peptides, it has been assumed that such binding occurs and that the amino
acid side chains that extend into the putative peptide binding site participate in this
interaction (11, 12). The results of the present study demonstrate that changes in
two residues in this site, 152 and 156, can affect presentation without abolishing
binding. The ability to make substitutions in amino acids in the peptide binding
site without loss of peptide binding suggests that there is a considerable degree of
flexibility in the interaction between peptide and the class I molecule. Thus, the
ability of a peptide antigen to stimulate class I-restricted CTL depends not only
on the ability of the peptide to bind to the class I molecule, but also the manner
in which it is presented.
Summary
Previous studies have suggested that MHC class I molecules bind and present
peptides to CTL in a manner that is analogous to the presentation of peptides by
class II molecules to Th. Crystallographic studies of HLA-A2 have led to the assign-
ment of a putative peptide binding site that is bordered by two a helices consisting
of residues 50-84 and 138-180. In this study, we have investigated whether residues
in the a2 helix are involved in the binding and/or presentation of a peptide to CTL.
We have generated CTL to type A influenza virus by stimulation of human PBL
with a synthetic peptide from the influenza A virus matrix protein (Ml residues
57-68) in the presence ofrIL-2. Such HLA-A2 .1-restricted influenza virus-immune
CTL do not recognize infected HLA-A2 .3+ targets. A2.1 and A2 .3 differ by three
amino acids in the a2 domain: Ala vs . Thr at position 149, Val vs. Glu at position
152, and Leu vs. Trp at position 156 . Site-directed mutants of the A2.1 gene that
encode A2 molecules that resemble A2 .3 at positions 149, 152, and 156 have been
constructed, transfected into human cells, and assayed for their ability to present
the M1 peptide. The results demonstrate that most, but not all, A2.1-restricted Ml-
peptide-specific CTL fail to recognize Ml peptide-exposed transfectants with cer-
tain single amino acid substitutions at positions 152 and 156. In contrast, Ml peptide-
exposed transfectants that express A2 molecules with an Ala - Thr substitution
at position 149 were recognized by all CTL tested, but they exhibited an apparent
difference in the kinetics of peptide binding. These results indicate that amino acid
substitutions at positions 152 and 156 of the putative peptide binding site of the A2
molecule can affect presentation without eliminating binding, and indicate that the
failure to recognize complexes between the peptide and the mutant A2 molecules
is due to different TCR specificities and not to the failure to bind the peptide.
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